Cancer immunotherapy can disable suppressive immune cells to aid tumor destruction news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Date Time
Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab
NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE:PFE) today announced that the first participant has been dosed in the registration-enabling Phase 2 MagnetisMM-3 study (NCT04649359) of elranatamab (PF-06863135), an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody, in patients with relapsed/refractory multiple myeloma. The study evaluates the efficacy and safety of elranatamab, administered subcutaneously, in patients with disease that is refractory to at least one agent in each of three major classes of medications approved for multiple myeloma. The study’s estimated primary completion date is June 2022.
Study suggests a new way to personalize anti-CTLA-4 therapy for cancers
A Ludwig Cancer Research study has identified a novel mechanism by which a type of cancer immunotherapy known as CTLA-4 blockade can disable suppressive immune cells to aid the destruction of certain tumors. The tumors in question are relatively less reliant on burning sugar through a biochemical process known as glycolysis.
Researchers led by Taha Merghoub and Jedd Wolchok of the Ludwig Center at Memorial Sloan Kettering Cancer Center (MSK) and former postdoc Roberta Zappasodi-;now at Weill Cornell Medicine-;have discovered that in a mouse model of glycolysis-deficient tumors, CTLA-4 blockade does much more than stimulate cancer-targeting T cells of the immune system.
Be Kind: Young cancer survivor hands out Valentine s Day care packages
WABC
Share:
Doctors diagnosed Elana Koenig, 12, with a form of sarcoma when she was just eight years old.
She beat the disease and went on to create the Koenig Childhood Cancer Foundation. Now, she is bringing smiles to other children like her.
On Sunday, Koenig handed out Valentine s Day gifts to patients at Ronald McDonald House and Memorial Sloan Kettering Cancer Center.
Each care package includes socks, candy bars, and toys.
Koenig says each item is meant to bring joy into the kids lives.
KEYTRUDA Plus LENVIMA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib, With a Median PFS of Nearly Two Years Versus Nine Months for Sunitinib
LENVIMA Plus. | February 16, 2021